Peter Libby: Managing Cardiovascular Risk in Clonal Hematopoiesis of Indeterminate Potential
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared a post on LinkedIn:
“What do we do to address cardiovascular risk in people with clonal hematopoiesis of indeterminate potential (CHIP) in the absence of clinical trial data? In our CHIP clinic, we practice aggressive preventive cardiology tuned to the particular CHIP and traditional risk factor profile of our patients in a transparent, shared decision-making mode. We summarize some of our approach in this Primer in JACC Cardiooncology paper.
We built this experience with serial fellows who worked with me in CHIP clinic, each now faculty members: Amy Lin UCSF, Aeron Small MGB/Harvard, and Ohad Oren Cleveland Clinic, who took the lead in this report. I’m proud of their successes! Nicholas Chiu is my current fellow, joining this lineage. Now we need to work together to generate the data to fill the evidence gap in managing CHIP!”
Title: Managing Cardiovascular Risk in Clonal Hematopoiesis of Indeterminate Potential: JACC: CardioOncology Short-Form Primer
Authors: Ohad Oren, Aeron M. Small, Amy E. Lin, Peter Libby
Read full paper here.
Stay updated with Hemostasis Today.
-
Nov 1, 2025, 18:00Kathleen Freson to Speak at the EHA SWG Scientific Meeting
-
Nov 1, 2025, 17:38Joshua Muia on Genetic Alterations Affecting ADAMTS13 Maturation at IPS 2025
-
Nov 1, 2025, 17:19Michael Makris Shares 2024 Annual Global Survey from the WFH
-
Nov 1, 2025, 16:45Erin VanDyke: This Month Was Full of Meaningful VTE Moments
-
Nov 1, 2025, 14:14Congratulations to South Africa’s first WSO Certified Essential Stroke Centers!
-
Oct 31, 2025, 13:47Bethany Brown and Colleagues Present Recommendations on DEHP Alternatives
-
Oct 30, 2025, 07:52Haemophilia B - An illustrative review of current challenges and opportunities
-
Oct 30, 2025, 05:14Umberto Pensato on Reperfusion Outcomes in Stroke
-
Oct 29, 2025, 07:39Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
-
Oct 29, 2025, 07:38Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 1, 2025, 17:04Ozlem Fidanci: Recognizing The Signs of a Stroke Can Save Someone You Love
-
Nov 1, 2025, 15:51Gülşah Türkoğlu: On World Stroke Day, We Came Together to Commemorate This Important Global Health Occasion
-
Nov 1, 2025, 15:05Nusaiba Masnurah Delivered A Speech on Surviving Thrombotic Events Werfen’s EEMEA Seminars
-
Nov 1, 2025, 14:47Rob Verhaeren at WSC 2025: Discover How Philips Technology Helps Accelerate Stroke Response
-
Nov 1, 2025, 13:58Rena Hirani Awarded the Inaugural James Isbister Prize at the Blood ISBT 2025